R Landman
Overview
Explore the profile of R Landman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
185
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Landman R, Marcelin A, Bennani M, Philippe C, Kousignian P, Finkielsztejn L, et al.
Infect Dis Now
. 2021 Dec;
52(2):93-100.
PMID: 34922034
Objectives: Dolutegravir is a second-generation integrase strand transfer inhibitor of particular interest as a rescue treatment for people living with HIV (PLWHIV) who develop resistance to multiple antiretrovirals (ART). We...
2.
Bachelard A, Isernia V, Vallois D, Le Gac S, Chalal L, Landman R, et al.
J Antimicrob Chemother
. 2021 Jun;
76(9):2484-2485.
PMID: 34109414
No abstract available.
3.
Landman R, Haffert S
Opt Express
. 2020 Jun;
28(11):16644-16657.
PMID: 32549483
Fourier-based wavefront sensors, such as the Pyramid Wavefront Sensor (PWFS), are the current preference for high contrast imaging due to their high sensitivity. However, these wavefront sensors have intrinsic nonlinearities...
4.
Supervie V, Assoumou L, Breban R, Lert F, Costagliola D, Pialoux G, et al.
J Antimicrob Chemother
. 2017 Sep;
72(11):3172-3176.
PMID: 28961977
Background: Individuals presenting for care with severe immunosuppression typically have high plasma HIV viral load (pVL) and may transmit HIV before and after initiation of combination antiretroviral therapies (cART). Patients...
5.
Marcelin A, Charpentier C, Wirden M, Landman R, Valantin M, Simon A, et al.
J Antimicrob Chemother
. 2012 Feb;
67(6):1475-8.
PMID: 22371439
Objectives: To compare the frequency of the selection of the M184V/I resistance mutation in HIV-infected patients who experienced virological failure while receiving emtricitabine (FTC) or lamivudine (3TC), administered with tenofovir...
6.
Larrouy L, Chazallon C, Landman R, Capitant C, Peytavin G, Collin G, et al.
Antimicrob Agents Chemother
. 2010 May;
54(7):2910-9.
PMID: 20439606
ANRS 127 was a randomized pilot trial involving naïve patients receiving two dual-boosted protease inhibitor (PI) combinations. Virological response, defined as a plasma HIV RNA level of <50 copies/ml at...
7.
Spire B, Arnould B, Barbier F, Durant J, Gilquin J, Landman R, et al.
HIV Clin Trials
. 2009 Sep;
10(4):215-32.
PMID: 19723610
Purpose: Questionnaires assessing patient-reported outcomes in HIV are either too long or not HIV-specific. Our aim was to develop and validate a simplified HIV patient questionnaire. Method: 607 HIV patients...
8.
Poupard M, Ngom Gueye N, Thiam D, Ndiaye B, Girard P, Delaporte E, et al.
HIV Med
. 2007 Mar;
8(2):92-5.
PMID: 17352765
Background: Efavirenz has been associated with neuropsychiatric disorders, but little is known about depression and quality of life in sub-Saharan Africa, where nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimens are still...
9.
Landman R, Descamps D, Peytavin G, Trylesinski A, Katlama C, Girard P, et al.
HIV Clin Trials
. 2006 Feb;
6(6):291-301.
PMID: 16452063
Background: To assess the efficacy and safety of the triple NRTI combination of abacavir (ABC), lamivudine (3TC), and tenofovir (TDF) in a once-daily regimen. Method: 38 HIV-naive patients (pts) were...
10.
Johnson M, Nieto-Cisneros L, Horban A, Arasteh K, Gonzalez-Garcia J, Artigas J, et al.
HIV Med
. 2005 Apr;
6(2):107-13.
PMID: 15807716
Objectives: To compare gastrointestinal (GI) tolerability and patient preference for the new 625 mg formulation of nelfinavir (NFV) and the marketed 250 mg tablets (Viracept) in HIV-1-infected patients. Methods: Virologically...